syn608

SYN608 is a small molecule inhibitor that targets poly(ADP-ribose) glycohydrolase (PARG), an enzyme critical for DNA damage repair in cells. By inhibiting PARG, SYN608 causes the accumulation of DNA damage, particularly killing tumor cells harboring homologous recombination repair (HRR) deficiencies, such as those with mutations in BRCA or ATM genes. The drug is being evaluated in phase 1 clinical trials for the treatment of advanced solid tumors, including prostate cancer, breast cancer, and ovarian cancer, with a focus on tumors with HRR deficiencies. Preclinical and early phase data suggest it may be effective even against cancers resistant to similar DNA repair-targeted therapies, with a promising safety profile and low cardiac risk. SYN608 was developed by SynRx Therapeutics Co., Ltd.[1][5][9]